Life Sciences INDUSTRIES

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.


Recognized as a leading life sciences practice, WilmerHale has represented life sciences clients across the United States and Europe for more than four decades. From biotechnology, pharmaceutical, diagnostic and medical device companies at all stages of growth to other institutions in the space, including venture capitalists, investment banks, universities and others, we understand the business of our life sciences clients and the changing regulatory and competitive demands they face.

Contacts

Sort By
Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

stuart.falber@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Der Marderosian, Lia

Lia Der Marderosian

Co-Chair, Corporate Practice Group

+1 617 526 6982 (t)

lia.dermarderosian@wilmerhale.com

johnson-brian.jpg

Brian A. Johnson

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

+1 212 937 7206 (t)

brian.johnson@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Capabilities

WilmerHale's Life Sciences Practice has extraordinary range, and the majority of our lawyers devote a significant portion of their practice to areas critical to life sciences clients. The firm's multi-disciplinary teams work seamlessly to handle a broad range of matters for clients, including corporate finance, licensing and strategic alliances, litigation, mergers and acquisitions, intellectual property, Food and Drug Administration (FDA), competition and other regulatory matters, and securities fraud. Our lawyers advise on venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protect clients' innovations through patent prosecution and portfolio development; and defend their interests in enterprise-critical patent litigation. We also represent life sciences clients in dealings with the United States and other governments on regulatory matters, including issues before the FDA and other agencies, merger clearance and enforcement actions, and public policy and strategy. Read about some of our recent life sciences transactions.

Our Life Sciences Practice includes corporate lawyers who have helped thousands of entrepreneurs successfully launch their businesses; raise billions in financing; and take their companies to sale, the public markets and/or through drug commercialization. We have a longstanding tradition of representing emerging companies and entrepreneurs across industries, and routinely offer the strategic advice and sharp business perspectives that are critical to our clients' success. Learn about our startup practice at WilmerHaleLaunch.com.

Publications & News

View

May 22, 2018

WilmerHale Counsels Accent Therapeutics in $40M Series A Financing

On May 18, 2018, Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced its $40M Series A financing to establish a discovery platform and pipeline of therapeutic candidates targeting RNA-modifying proteins.

May 17, 2018

WilmerHale Partners and Practices Named Among Managing Intellectual Property's 2018 IP Stars

Managing Intellectual Property's 2018 IP Stars Handbook recognizes WilmerHale and 19 of its partners as leaders in the field. IP Stars identifies lawyers based on their knowledge, outcomes achieved for clients and unique strengths in the given practice area.

May 8, 2018

WilmerHale Counsels Karyopharm Therapeutics in Public Offering of Shares

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, has announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters' option to purchase additional shares.

May 3, 2018

WilmerHale Lawyers and Practices Recognized in 2018 Edition of Chambers USA

Chambers and Partners announced its rankings for the 2018 edition of Chambers USA: America's Leading Lawyers for Business, with WilmerHale listed among the nation's best in 50 practice area categories. Chambers also ranked 95 WilmerHale lawyers as leaders in their respective fields.

April 18, 2018

WilmerHale Counsels PerkinElmer in €300M Bond Offering

On April 11, multinational human and environmental health corporation, PerkinElmer, Inc., announced the closing of a €300 million bond offering.

April 11, 2018

WilmerHale Counsels Analogic in $1.1B Acquisition by an Affiliate of Altaris Capital Partners

On April 10, 2018, Analogic Corporation, a provider of leading-edge healthcare and security solutions, and Altaris Capital Partners, LLC, a leading private investment firm with expertise in Analogic's end markets, announced that they have entered into a merger agreement under which Analogic will be acquired by Altaris for approximately $1.1 billion on a fully diluted basis.

April 5, 2018

Brexit at Halfway: Pharma and Medical Devices

The object of this Alert is to highlight some practical implications of Brexit for the supply of pharmaceutical products and medical devices in the European Union (EU) and related action items which companies should be considering if they have not done so before.

April 4, 2018

Important New Patent Term Adjustment Decision Allowing Post-RCE B Delay

A recent decision calls into question the US Patent and Trademark Office regulation providing that B delay stops accruing as soon as a Request for Continued Examination is filed.

March 21, 2018

Selected 2018 M&A Transactions

In 2017, we advised clients on more than 75 M&A transactions with an aggregate value of approximately $60 billion, providing guidance in areas including corporate, securities, antitrust and tax. Since 2007, we have participated in more than 1,000 mergers and acquisitions with a total value in excess of $400 billion, ranging from sales of VC-backed companies to multibillion-dollar global mergers.

March 21, 2018

Selected 2018 Public Offerings and Rule 144A Placements

In 2017, we handled more than 40 public offerings and Rule 144A placements raising approximately $18 billion, for leading companies in life sciences, technology, financial services, communications and other industries. Since 2007, we have served as counsel in approximately 400 public offerings and Rule 144A placements with total proceeds in excess of $150 billion.

Recognition

  • Chambers USA: America's Leading Lawyers for Business - Named WilmerHale a top law firm for life sciences from 2007-2017 with sources saying our attorneys are "responsive, efficient and very technically sophisticated." 
  • Chambers Global - Recognized WilmerHale as a leader in life sciences from 2013-2017, and noted that sources appreciate the firm's “client service, commerciality and value for money.”
  • Chambers Europe - Recognized WilmerHale as a leader in life sciences in Germany in its 2013-2017 editions.
  • In Vivo – Named Regeneron's novel deal with Decibel Therapeutics, represented by WilmerHale, as the Top Alliance 2017 Deal of the Year.
  • Lake Whillans - The Life Sciences Law Firm Index included WilmerHale among the top three best life sciences law firms (2016, 2017), as the top firm for startup work (2017), among the top 10 deal firms (2017), the top two patent law firms (2016) and top 10 firms for thought leadership (2016).
  • Law360 - Named WilmerHale a Technology Practice Group of the Year for 2016 and a Life Sciences Practice Group of the Year for 2013 in its annual rankings, which recognize firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year.
  • LMG Life Sciences - Named WilmerHale the Life Cycle Firm of the Year in 2017 and awarded the firm one of five Finance and Transactional Impact Cases of the Year for counseling Editas Medicine in its licensing and collaboration with Allergan. LMG ranked the firm in its 2012-2017 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations, and previously named WilmerHale a Life Cycle Firm in 2012-2015. In 2013, WilmerHale was named the winner of the Canadian Impact Deals of the Year award, in recognition of its representation of Enobia Pharma in its acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP - Recognized WilmerHale as one of the best in the United States for life sciences from 2013-2016. In 2013, 2016 and 2017, WilmerHale was named the "Patent Contentious Firm of the Year" and in 2013, the "Pharmaceutical IP Litigation Firm of the Year."
  • The American Lawyer - Placed WilmerHale on its 2016 "A-List" as one of the United States' leading law firms, marking the 13th year the firm received that recognition.
  • The American Lawyer - Named WilmerHale the 2014 IP Litigation Department of the Year and a finalist for its 2016 IP Litigation Department of the Year. The firm has been named a winner twice and a finalist six times since the contests launch in 2004.
  • The BTI Consulting Group Inc. - Named WilmerHale among the top 10 law firms for having strong and lasting client relationships with the pharma industry in its BTI Power Rankings 2016 report.
  • The Legal 500 US - Ranked WilmerHale among the top law firms for life sciences from 2013-2017 with sources saying the firm "brings a great deal of experience to any situation" and "has access to additional expertise/resources to help solve any problem."
  • The National Law Journal - Named WilmerHale to its 2012-2015 Intellectual Property Hot List, which honors firms that demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News - Best Lawyers® - Recognized the firm in its 2014-2017 "Best Law Firms" lists in the first tier nationally for biotechnology law, corporate law, intellectual property litigation, patent law, securities and venture capital law. In 2017, WilmerHale received first-tier metropolitan rankings in Boston intellectual property litigation, patent law, technology law and venture capital law; in Colorado for intellectual property litigation; in New York for biotechnology law and corporate law; in San Jose for patent litigation; and in Washington DC for intellectual property litigation.